Cargando…
Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
Advanced osteosarcomas (OSs) and Ewing sarcomas (ESs) tend to have poor prognosis with limited therapeutic options beyond first-line therapy. Aberrant angiogenesis and MET signaling play an important role in preclinical models. The anti-angiogenic drug cabozantinib was tested in a phase 2 trial of a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918141/ https://www.ncbi.nlm.nih.gov/pubmed/36769769 http://dx.doi.org/10.3390/jcm12031119 |
_version_ | 1784886540453806080 |
---|---|
author | Kokkali, Stefania Kyriazoglou, Anastasios Mangou, Elpida Economopoulou, Panagiota Panousieris, Michail Psyrri, Amanda Ardavanis, Alexandros Vassos, Nikolaos Boukovinas, Ioannis |
author_facet | Kokkali, Stefania Kyriazoglou, Anastasios Mangou, Elpida Economopoulou, Panagiota Panousieris, Michail Psyrri, Amanda Ardavanis, Alexandros Vassos, Nikolaos Boukovinas, Ioannis |
author_sort | Kokkali, Stefania |
collection | PubMed |
description | Advanced osteosarcomas (OSs) and Ewing sarcomas (ESs) tend to have poor prognosis with limited therapeutic options beyond first-line therapy. Aberrant angiogenesis and MET signaling play an important role in preclinical models. The anti-angiogenic drug cabozantinib was tested in a phase 2 trial of advanced OS and ES and was associated with clinical benefits. We retrospectively analyzed the off-label use of cabozantinib in adult patients with advanced OS and ES/primitive neuroectodermal tumors (PNETs) in three centers of the Hellenic Group of Sarcoma and Rare Cancers (HGSRC). Between April 2019 and January 2022, 16 patients started taking 60 mg of cabozantinib for advanced bone sarcoma or PNET. Median age at cabozantinib initiation was 31 years (17–83). All patients had received peri-operative chemotherapy for primary sarcoma and between 0 and 4 lines of treatment (median; 2.5) for advanced disease. The most common adverse effects included fatigue, anorexia, hypertransaminasemia, weight loss, and diarrhea. One toxic death was noted (cerebral hemorrhage). Dose reduction to 40 mg was required in 31.3% of the patients. No objective response was noted, and 9/16 patients exhibited stable disease outcomes. Progression-free survival varied from 1 to 8 (median; 5) months. Our study demonstrates that cabozantinib has antitumor activity in this population. In the real-life setting, we observed similar adverse events as in the CABONE study and in other neoplasms. |
format | Online Article Text |
id | pubmed-9918141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99181412023-02-11 Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers Kokkali, Stefania Kyriazoglou, Anastasios Mangou, Elpida Economopoulou, Panagiota Panousieris, Michail Psyrri, Amanda Ardavanis, Alexandros Vassos, Nikolaos Boukovinas, Ioannis J Clin Med Article Advanced osteosarcomas (OSs) and Ewing sarcomas (ESs) tend to have poor prognosis with limited therapeutic options beyond first-line therapy. Aberrant angiogenesis and MET signaling play an important role in preclinical models. The anti-angiogenic drug cabozantinib was tested in a phase 2 trial of advanced OS and ES and was associated with clinical benefits. We retrospectively analyzed the off-label use of cabozantinib in adult patients with advanced OS and ES/primitive neuroectodermal tumors (PNETs) in three centers of the Hellenic Group of Sarcoma and Rare Cancers (HGSRC). Between April 2019 and January 2022, 16 patients started taking 60 mg of cabozantinib for advanced bone sarcoma or PNET. Median age at cabozantinib initiation was 31 years (17–83). All patients had received peri-operative chemotherapy for primary sarcoma and between 0 and 4 lines of treatment (median; 2.5) for advanced disease. The most common adverse effects included fatigue, anorexia, hypertransaminasemia, weight loss, and diarrhea. One toxic death was noted (cerebral hemorrhage). Dose reduction to 40 mg was required in 31.3% of the patients. No objective response was noted, and 9/16 patients exhibited stable disease outcomes. Progression-free survival varied from 1 to 8 (median; 5) months. Our study demonstrates that cabozantinib has antitumor activity in this population. In the real-life setting, we observed similar adverse events as in the CABONE study and in other neoplasms. MDPI 2023-01-31 /pmc/articles/PMC9918141/ /pubmed/36769769 http://dx.doi.org/10.3390/jcm12031119 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kokkali, Stefania Kyriazoglou, Anastasios Mangou, Elpida Economopoulou, Panagiota Panousieris, Michail Psyrri, Amanda Ardavanis, Alexandros Vassos, Nikolaos Boukovinas, Ioannis Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers |
title | Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers |
title_full | Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers |
title_fullStr | Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers |
title_full_unstemmed | Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers |
title_short | Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers |
title_sort | real-world data on cabozantinib in advanced osteosarcoma and ewing sarcoma patients: a study from the hellenic group of sarcoma and rare cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918141/ https://www.ncbi.nlm.nih.gov/pubmed/36769769 http://dx.doi.org/10.3390/jcm12031119 |
work_keys_str_mv | AT kokkalistefania realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers AT kyriazoglouanastasios realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers AT mangouelpida realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers AT economopouloupanagiota realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers AT panousierismichail realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers AT psyrriamanda realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers AT ardavanisalexandros realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers AT vassosnikolaos realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers AT boukovinasioannis realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers |